Presenter's Information
Eberhard Grube, MD
Country | Germany |
Specialty | Interventional Cardiologist |
- TAVR 2024: What Do We Know and What is Still Missing?
- Essentials of Lifetime Management of Aortic Disease: Updated and Novel Points in 2024
- AS Lifetime Management
- EVOLUT: New Trials, New Technologies (OPTIMIZE PRO and SMART)
- TAVR is Better
- How to Prevent TAVR Complications with New TAVR Devices
- Next Innovation in Transcatheter Valve Intervention: New Techniques and New Valves
- Optimal TAVR Procedure for Bicuspid AV: Self Expandable Device
- Novel Implant Techniques: What is Different?
- Minimizing Embolic Events: Latest TAVR Data
- The Next Target of the Valvular Intervention: Future Perspectives
- Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations
- Percutaneous Mitral Valve Repair: Current Status and Future Perspectives
- Future Perspectives for TAVR - What Is Remained?
- TAVR in 2019: Appropriate Patient and Device Selection
- Evolut PRO Latest Innovation in TAVI: A Workhorse Device to Treat All Patient
- Cerebral Protection in TAVR: Which Patient Category or Anatomical Subset?
- Next Generation TAVR Devices
- TAVR Will Be a New Standard Even for Low-risk Patients
- Cerebral Embolic Protection: Routine or Selective
- MitraClip and TMVR Complications and Failures
- Cerebral Protection Device During TAVI: State of the Art
- TAVR vs SAVR in 2018: Updated Guidelines and Appropriate Use Criteria
- Rapid Changing TAVR Story: Predicting the Future from Ongoing TAVR Clinical Trials
- European Registry
- Severe Calcification: Avoid or Overcome
- Coronary or Cerebral Protection: When and How?
- Complex TAVR for Specific Challenging Cases - How to Do in Practice?
- New Mainstream TAVR
- TAVR of High-Risk/Complex Patients: For Whom and with?
- Building Evidence for Treating Lower Risk Patients: Recent Updates From Evolut R Technology and Evidence
- [Featured Lecture] \"TAVI Perspective 2017: Current Situation - Controversy - Prospect\"
- SURTAVI: Step-by-Step Moving Forward to Low Risk and Younger Patients
- Evolut R
- Ongoing TAVR Trials and Updating TAVR Guidelines
- Cerebral Embolic Protection During TAVR
- Update on Medtronic Intrepid Transcatheter Mitral Valve Replacement
- Monitoring Conduction Disturbance and Avoiding Permanent Pacemaker
- TAVR in Lower Risk
- Evolut R
- Evolving Trends in Complications After TAVR
- How Evolut R Has Impacted My Practice?
- Mechanical Expanded Lotus Valve
- Do We Need a Dedicated Bifurcation Stent or Is This a Niche Device?
- Next Generation Valve System Addressing Current TAVR Limitations
- Why I Select Self Expandable Valve.
- Valve in Valve Implants for Failed Bioprosthetic Heart Valves
- Ultimate Comparison: Sapien vs. Corevalve
- Which TAVI Devices to Use: A Multi-Device Patient-Specific Approach
- Stroke Prevention: When and How
- Boston Lotus: Transfemoral
- Beyond the First-generation Devices
- European Registry: Sapien vs. Core
- New TAVI Devices
- Beyond High-risk Patients: Will TAVR Replace Surgical AVR?
- Registry Results of Self-expandable CoreValve Studies
- Dedicated Bifurcation Stent
- New TAVI Systems
- Medtronic: CoreValve Evolut and Engager TAVI System
- European Outcomes of CoreValve Registry
- Durability of Sapien Valve and CoreValve
- Taped Lives: Implantation of CoreValve, Transaxilla or Transaortic
- Technology and Procedural Changes
- Core Valve Enough !
- Upcoming New Devices
- Alternative Approach with Core Valve: Transaxillary and Others
- Implantation: Rapid Pacing, Pre-and Post-dilation
- Taped Live Case: Core Valve 2
- TAVI; Evidence, Controversy, Complications, and Future Perspective
- Invited Case Presentation & Focus Review: Aortic Valve Intervention(Core Valve)
- Taking DES Technology from Concept to Clinical Proof
- Which One Is Better?- Edwards or CoreValve or Others?: CoreValve Is Better!
- Valve-in-Valve TAVI
- Case Selection for TAVR: Beyond the High-risk Patient
- Evidence Based Medicine: Does BioMatrixTM Bring Patient Benefit? - 3 Yr/Subgroup Follow Up from LEADERS Trial
- Case Presentation of the First Restenosed Core Valve Prosthesis: Treatment Solution!
- BIOFREEDOM: Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents
- Incidence and Treatment of Procedural Complications
- TAVI Perspectives from the European Theatre: New Indications and Multiple Devices
- Pitfalls During the TAVI (Core Valve) Implantation and How to Treat Them\".
- Dedicated Bifurcation and Left Main Stents
- An Update of the Self Expanding Medtronic/Core Valve TAVI
- The Core Valve Experience from the Siegburg Heart Center. An Update.
- New TAVI Devices: More of the Same or Meaningful Differences?
- Next Generation on PAVR Technologies
- New Approach to Treating Thrombus- Containing Lesions
- Interventionalist Perspective: The Treatment Pathway Was Shifted !
- New Stent Platforms
- Update on the Core Valve Experience
- The Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent FIM Experiences
- Percutaneous Aortic Valve Implantation
- Drug Eluting Stents (Bifurcation and Left Main Approach)
- The Xtent™ DES System: The Single Solution for Multilesion, Multivessel, and Long Lesion Treatment
- Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US NOBORI Clinical Trial Program
- Current Data Indicates No Clinically Relevant Differences Between CYPHER and TAXUS!
- Everolimus Drug-Eluting Stents I: Review of Guidant FUTURE I and II, and Status Update of FUTURE III and IV
- The Biolimus A9 DES Program (Focus on Stealth 1)
- Is the TAXUS Stent Benefit Extended to the Most Complicated Patients and Lesions?
- New Drug-Eluting Stents: Everolimus (FUTURE-I and -II) and More